Is your product a medical device?
This is the question that sets your timeline. Software that diagnoses, predicts or informs treatment decisions may count as a medical device, which in the UK means working with the MHRA's requirements and, for Europe, the EU MDR. Administrative tools such as scheduling, documentation or operational analytics usually face a lighter path.
Investors will want to know your likely classification, the evidence you will need and how long it will take. An honest answer here builds more confidence than an optimistic one.
Evidence investors expect
Performance on a retrospective dataset is a starting point, not proof. Investors look for validation on data the model has not seen, evidence from real clinical settings and, over time, outcomes that matter to buyers: time saved, errors avoided, patients seen or costs reduced.
- Clinical champions who use the product and will speak to investors.
- A data access and governance arrangement that is lawful and sustainable.
- Published or independently reviewed validation where possible.
- A plan for monitoring performance after deployment.
Selling into healthcare
Selling to the NHS can be slow and fragmented, with decisions made at trust, regional or national level and frameworks that govern procurement. Private healthcare providers, insurers, life sciences companies and direct-to-patient models can move faster but have their own requirements. Strong pitches show a first market that can pay now, with a route to broader adoption later.
What slows healthtech rounds
Healthtech is one of the most diligence-heavy sectors. Common issues include:
- Unclear or underestimated regulatory classification.
- Pilots funded by innovation budgets with no path to recurring budget.
- Dependence on one data partner without long-term access rights.
- Clinical safety processes that exist on paper only.
Healthtech product types and their typical path
| Product type | Regulatory burden | Typical first buyer | Evidence focus |
|---|---|---|---|
| Administrative and workflow tools | Lower | Providers, clinics | Time and cost saved |
| Clinical decision support | Higher, often a medical device | Providers, specialists | Accuracy and clinical outcomes |
| Consumer health and wellness | Varies by claims made | Patients, employers | Engagement and retention |
| Life sciences tools | Varies | Pharma and research | Speed and cost of R&D |
Questions to prepare before you pitch
- What regulatory class do you expect, and what evidence will it require?
- Who pays, and from which budget line?
- How did you access your training data, and do you keep the right to use it?
- Which clinicians use your product, and what do they say about it?
- How do you monitor for performance drift after deployment?
- What happens to your plan if approval takes twice as long as expected?
How KJ Enterprises evaluates healthtech businesses
KJ Enterprises looks at healthtech businesses where the regulatory path is understood, the buyer is clear and AI delivers a measurable operational or clinical benefit. We are realistic about timelines and value founders who are too.
If that describes your company, you can apply for investment. Related reading: machine learning funding and applied AI funding.
Frequently asked questions
Can a healthtech startup raise before regulatory approval?
Yes. Many raise pre-approval rounds, but investors expect a clear plan, budget and timeline for the approvals and clinical evidence the product will need.